The Texas Heart Institute
J

Heart Failure in Women: What Is the Epidemiology?

By The Texas Heart Institute FEATURING Jerry D. Estep
By The Texas Heart Institute FEATURING Jerry D. Estep
10 views
April 20, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
Medical College of Georgia - Augusta University

Cardiovascular Summit at Kiawah 2024

Thu, Jul 18, 2024
49:28
Critical Care Cardiology Education Summit

Foolish Heart: Acute Complications in Adult Congenital Heart Disease…

Feat. C. Martin
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
29:08
Scripps Health

Case Presentation: Complex PCI with IABP

Feat. R. Khedraki, T. Heywood, R. Mohan, A. Srivastava
15:47
Scripps Health

HFpEF in Women

Feat. B. Borlaug
35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
17:08
CVRx | Barostim

Integrating Barostim into a Comprehensive Heart Failure Program ISHL…

Feat. D. Yaranov, P. Patel, R. Gupta, J. Schmitto, E. Chung
18:48
Right Care Initiative

Precision Medicine in Menopause: How Times Have Changed!

Feat. K. Adams
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim
17:29
UCLA Health

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

Feat. D. Vucicevic
12:09
ARCH Advanced Revascularization Symposium

End-Stage Heart Failure Therapies

Feat. D. Horstmanshof
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
17:22
Samuel Sherratt

Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Has High Membrane Affi…

34:18
Scripps Health

Cancer Survivorship: How To Monitor for Cardiac Disease Following Tr…

Feat. A. Kuo
12:30
Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg
20:59
Mary E. Money

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

84:17
Jefferson Health

2022 Heart Failure Guidelines Review

Feat. D. Haas